Rigetti Computing Stock Soars As Defense Contracts Fuel Long Term Quantum Growth - TIKR.com
π Rigetti Computing secured a letter of intent with the U.S. Department of Commerce for up to $100 million in CHIPS Act funding to support R&D on superconducting quantum chips.
π€ The company launched a new collaboration with HPE and the Pittsburgh Supercomputing Center to build a hybrid quantum-classical system.
π° Q2 revenue reached $5.1 million, up from $1.8 million a year ago, driven by on-premises Novera QPU sales.
π Gross margins improved to approximately 43% from 31% a year earlier.
πΈ GAAP net loss widened to $52.6 million due to non-cash warrant and earn-out adjustments, while non-GAAP loss was $16 million.
π΅ Rigetti holds a strong cash position of $541.3 million with no debt, ensuring runway for future investments.
π The company's stock has risen roughly 7.7 times over the past three years.
βοΈ Rigetti operates the 108-qubit Cepheus system, one of only three gate-based systems in the world above 100 qubits.
ποΈ Bulls point to multi-year government and defense contracts with AFRL and DARPA's QBI program as a path toward stable recurring revenue.
βοΈ Bears argue the stock trades at a premium price-to-book ratio of 10.2x, pricing in future technical milestones that have not yet occurred.
- Rigetti secured a letter of intent with the U.S. Department of Commerce for up to $100 million in CHIPS Act funding to support R&D on superconducting quantum chips.
- Q2 revenue surged to $5.1 million from $1.8 million a year ago, driven by sales of its on-premises Novera QPU.
- Gross margins improved significantly to approximately 43% from 31% a year earlier.
- The company maintains a strong cash position of $541.3 million with no debt, providing ample runway for continued investment.
- Rigetti operates the 108-qubit Cepheus system, one of only three gate-based systems globally exceeding 100 qubits.
- The company has multi-year government and defense contracts with AFRL and continues participation in DARPA's QBI program.
- GAAP net loss widened to $52.6 million compared to $39.7 million last year, largely due to non-cash warrant and earn-out adjustments.
- The company is still early in turning research breakthroughs into real, scalable revenue.